When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.

Telehealth company Hims & Hers Health (HIMS) recently stirred up controversy with its ad promoting its compounded weight-loss ...

Listen to more stories on the Noa app. The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission. Nobody really looks forward to reading a Hims review. But hair loss comes for us ...

Compounded GLP-1s are typically much cheaper and can serve as an alternative for patients who are navigating complex supply hurdles and spotty insurance coverage. Hims & Hers sells compounded ...